In a research note published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on NPS Pharmaceuticals (NPSP) with a $44 price target, ahead of NPSP’s upcoming second quarter …
In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on NPS Pharmaceuticals, Inc (NPSP) with a …
